The Treatment of Myeloid Malignancies with Kinase Inhibitors, An Issue of Hematology/Oncology Clinics of North America, E-Book

The Treatment of Myeloid Malignancies with Kinase Inhibitors, An Issue of Hematology/Oncology Clinics of North America, E-Book
Author: Ann Mullally
Publisher: Elsevier Health Sciences
Total Pages:
Release: 2017-07-14
Genre: Medical
ISBN: 0323532365

This issue of Hematology/Oncology Clinics will focus on The Treatment of Myeloid Malignancies with Kinase Inhibitors. Articles will focus on: Targeting aberrant signaling in myeloid malignancies: promise versus reality; The development and use of imatinib for the treatment of chronic myelogenous leukemia; Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors; Tyrosine kinase inhibitors in the treatment of systemic mastocytosis and hypereosinophilic syndrome; The development and use of JAK2 inhibitors for the treatment of myeloproliferative neoplasms (MPN); Mechanisms of resistance to JAK2 inhibitors in MPN; Kinase inhibitor screening in myeloid malignancies; and more!

Myeloproliferative Neoplasms, An Issue of Hematology/Oncology Clinics of North America

Myeloproliferative Neoplasms, An Issue of Hematology/Oncology Clinics of North America
Author: John Mascarenhas
Publisher: Elsevier Health Sciences
Total Pages: 240
Release: 2021-02-27
Genre: Medical
ISBN: 0323795897

This issue of Hematology/Oncology Clinics, guest edited by Drs. Ronald Hoffman, Ross Levine, John Mascarenhas, and Raajit Rampal, is dedicated to Myeloproliferative Neoplasms. This issue is one of six selected each year by the series consulting editors, Drs. George P. Canellos and Edward J. Benz. Topics in this issue include—but are not limited to— Overview of pathophysiology and potential drug targets, The role of the megakaryocyte, Epigenetics, Genetics, Novel technologies for understanding MPN biology, Important pathology considerations, Current Clinical investigations, Quality of life, Application of stem cell therapy, Immunotherapy approaches, Clinical unmet needs in ET/PV, Accelerated and blast phase MPNs, Epidemiology, Thrombotic and hemorrhagic complications, Murine modeling, The microenvironment in MPNs, MDS/MPN overlap syndrome, and Advancing effective clinical trial designs.

Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North America

Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North America
Author: Ross Levine
Publisher: Elsevier Health Sciences
Total Pages: 193
Release: 2012-10-28
Genre: Medical
ISBN: 1455747645

Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Author: Uday R. Popat
Publisher: Nova Science Publishers
Total Pages: 0
Release: 2014
Genre: Chronic myeloid leukemia
ISBN: 9781629489711

Targeted therapy has revolutionised modern oncology practice and has completely changed the outcome of once universally fatal diseases like chronic myeloid leukaemia (CML). The last decade has witnessed significant advances in the management of CML, which has become more like a chronic disease. Written by experts in the field, this volume nicely describes the current knowledge of the pathophysiology, clinical features, and management of CML. It covers not only clinical topics but also the basic science underlying these practices. It will be of help to clinicians and basic scientists alike. In addition to the state of the art treatment of CML, this book also covers many uncommon but very important special topics like management of CML in pregnancy or with children, management of resistance to new tyrosine kinases and treatment of the advanced phase of the disease. Written to be easily digestible, patients will also be able to access important and universally useful information on CML (eg: diagnosis, symptoms and signs, and treatment). Some themes especially, including drug and food interactions of tyrosine kinase inhibitors (TKIs), CML treatment during pregnancy, advantages/disadvantages of the most commonly used TKIs, and bone marrow transplantation indications, will be of popular concern. This extensively referenced book therefore should be of great help to both novices and experts in the field.

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
Author: Rüdiger Hehlmann
Publisher: Springer
Total Pages: 261
Release: 2016-08-17
Genre: Medical
ISBN: 3319331981

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the forthcoming impact of availability of generic imatinib.

Central Nervous System Malignancies, An Issue of Hematology/Oncology Clinics of North America, E-Book

Central Nervous System Malignancies, An Issue of Hematology/Oncology Clinics of North America, E-Book
Author: David A. Reardon
Publisher: Elsevier Health Sciences
Total Pages: 313
Release: 2021-11-24
Genre: Medical
ISBN: 032381073X

In this issue of Hematology/Oncology Clinics, guest editor David A. Reardon? brings his considerable expertise to the topic of Central Nervous System Malignancies. Top experts in the field cover key topics such as CNS Metastases, Leptomeningeal Disease, Neurofibromatoses, Imaging Advances for CNS Tumors, and more. Contains 16 relevant, practice-oriented topics including CNS Tumor Classification: An Update on the Integration of Tumor Genetics; Etiology and Epidemiology of CNS Tumors; The Evolving Role of Neurosurgical Intervention for CNS Tumor ; Update on Radiation Therapy for CNS Tumors; and more. Provides in-depth clinical reviews on CNS Malignancies, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America, E-Book

Chronic Lymphocytic Leukemia, An Issue of Hematology/Oncology Clinics of North America, E-Book
Author: Jennifer R. Brown︎
Publisher: Elsevier Health Sciences
Total Pages: 217
Release: 2021-07-01
Genre: Medical
ISBN: 0323896936

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown?, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

Congenital and Acquired Disorders of Macrophages and Histiocytes, An Issue of Hematology/Oncology Clinics of North America

Congenital and Acquired Disorders of Macrophages and Histiocytes, An Issue of Hematology/Oncology Clinics of North America
Author: Nancy Berliner
Publisher: Elsevier Health Sciences
Total Pages: 193
Release: 2016-01-07
Genre: Medical
ISBN: 0323400892

This issue of Hematology/Oncology Clinics of North America is devoted to Congenital and Acquired Disorders of Macrophages and Histiocytes. Guest Editors Nancy Berliner, MD and Barrett Rollins, MD have assembled a group of expert authors to review the following topics: Nosology of Langerhans Cell Histiocytosis (LCH); Cell of Origin of LCH; Genomic Changes in LCH; Clinical Treatment of LCH; Neurodegeneration in LCH; Pathogenesis of Hemophagocytic Lymphohistiocytosis (HLH); Familial HLH; HLH in Adults; Macrophage Activation Syndrome; and Stem Cell Transplant for HLH.

Chemotherapy for Leukemia

Chemotherapy for Leukemia
Author: Takanori Ueda
Publisher: Springer
Total Pages: 354
Release: 2017-04-17
Genre: Medical
ISBN: 9811033323

This book focuses on the latest progress in chemotherapy for leukemia and related diseases, including still-ongoing but promising studies. The effectiveness of treatment for chronic myeloid leukemia and acute promyelocytic leukemia has been dramatically improved in recent years. This improvement has been made possible with the development of molecular targeted agents such as bcr-abl tyrosine kinase inhibitors and all-trans retinoic acid. The antibody for the unique target of chemokine receptor 4 for adult T-cell leukemia/lymphoma, or FLT3 inhibitors (signaling inhibitors) has been applied to other leukemias. Also, chemotherapeutic agents including antimetabolite analogues such as clofarabine, and azacitidine (an epigenetic regulator) have undergone progressive development. Meanwhile, the novel concept of therapy targeting leukemic stem cells has been developed. The contributors discuss prospective results of basic and preclinical studies and clinical possibilities based on the effects for leukemic stem cells. This work facilitates a comprehensive understanding of modern treatment methodology for leukemia. The volume therefore will greatly benefit not only hematologists but also oncologists, all physicians who specialize in blood cancer, and pharmacologists who are involved in the development of therapeutic agents for leukemia.